Sharps Technology is a medical device company addressing global issues while engineering a safer future for healthcare providers and people everywhere through compassionate innovation. Sharps’ line of smart safety syringes eliminates accidental needlestick injuries, prevents needle reuse, and reduces wasted vaccines and medicine while retaining the intuitive simplicity of traditional syringes. Sharps Technology aims to be a solution provider for the advancement of future drug delivery systems.

1. Specialized Drug Delivery Technology for
Pharmaceutical and Healthcare Markets
December 2022
Nasdaq: STSS

2. This presentation of Sharps Technology, Inc. (the “Company”) contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform and other securities laws. Words such as “expects,”
“intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are
intended to identify forward-looking statements. For example, the Company is using forward-looking statements
when it discusses its vision, the potential of its product, its strategy, market potential for its products, its paradigm,
commercialization of its products, and use of its product candidates and its future growth. This presentation
also contains estimates with respect to the Company’s economics model. Forward-looking statements are
not historical facts, and are based upon management’s current expectations, beliefs and projections,
many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are
expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and
projections will be achieved, and actual results may differ materially from what is expressed or indicated by the
forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could
cause actual performance or results to differ materially from those expressed in the forward-looking statements.
For a more detailed description of the risks and uncertainties affecting the Company, the reference is
made to the Company’s reports filed from time to time with the Securities Commission (the “SEC”), including,
but not limited to, the risks detailed in the Company’s preliminary prospectus dated March 30, 2022, filed with
the S
E
C as a part of the Company’s Registration Statement on Form S-1 (File No. 333-263715), and
documents incorporated by reference therein. Forward-looking statements speak only as of the date the
statements are made. The Company assumes no obligation to update forward- looking statements to reflect
actual results, subsequent events or circumstances, changes in assumptions or changes in other factors
affecting forward-looking information except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no inference should be drawn that the
Company will makeadditional updates with respect thereto or with respect to other forward-looking statements.
Forward looking-Statements
2

3. A TRANSFORMATIVE 2022 to 2023
3
• Frompre-revenuetorevenue
• Frompre-manufacturingtocommercial production
• Fromvial drawndesigntopre-fillablesolutions
• FromnoU.S.presencetoafactoryinS.C.
• FromnopharmaceuticalpartnertoNephron-
• Manufacturing
• Sales
• Distribution
• Pipelineoffuturebusiness
• Opportunityforexpansiontoourownfacility

4. Overview
• Foundedin 2017 (IPO in 2022) with a vision to develop innovative drug delivery technology for the healthcare
industry
 Strong product line of patented smart safety syringe systems.
 Products are FDA,WHOand CEMark approved and cleared for use by Pfizer and Moderna.
 In 2023 Sharps pre-filled syringe (PFS)systems will be launched covering volumetric delivery of 1, 2.25, 5, 10
and 50mL, including dual chamber systems.
• Nephron collaborationaccelerates near-term revenue for (PFS)commercialization and expanded manufacturing
 Transformative manufacturing agreement to produce with a state-of-the-art manufacturing facility.
 Pharma Services Program to develop a pipeline for future growth w/specialized packaging opportunities to
support fill / finish projects for industry customers.
 Specialized distribution and sales agreement for Sharps products with access to 3000+ customers
 Opportunity to expand manufacturing capabilities for growth initiatives w/100 million additional PFSproducts
• Growingspecialty syringe market that includes all applications targeting healthcare and pharma customers
• Strongmanagementteam with extensive experience in drug delivery manufacturing and product development
4

5. Nephron
Manufacturing
and Research
Partnership
MANUFACTURING AGREEMENT
5
• Sharps to Supply PFSproducts w/initial starting
capacity of 20 million units year
PHARMASERVICESPROGRAM
• Sharps drug delivery system knowledge with
Nephron’s fill finish and cleanroom designs to
service start-up med device companies
DISTRIBUTION& SA
LESOFSHARPSSMART
SAFETYSYRINGES
• Nephron’s distribution services to sell &
distribute Sharps products to their 3000+
healthcare customers
MANUFACTURING EXPANSION
• 100+ million PFSfor rapid expansion
opportunities to service demand for Billions of
annual prefilled syringe needs

6. Product Line: Disposable Smart Safety Syringes
• Ultra Low Waste
• Integrated PassiveRecessed
Safety System
• Pending FDA510k
submission
• EtOsterilized
• Vial Draw – sizes TBD
• Ultra Low Waste
• Integrated Active Recessed
Safety System
• Re-use Prevention
• FDAapproved
• WHOapproved
• CEMark
• EtOsterilized
• Vial Draw Sizes1ml -10ml
• Ultra Low Waste
• Integrated PassivePEEK
Safety System
• FDAapproved
• EtOsterilized
• Vial Draw 0.30ml – 3ml
Manufactured in Sharps’Hungary Facility 6

7. Disposable Smart Safety Syringes Market
7

8. 1ML LONG SILICONE
FREE
8
DUAL CHAMBER
SYSTEMS
2.25ML
1ML
SHORT
PREFILLED SYRINGE PLATFORM
• Highgradepolymer resin provides
great drugstability
• Shatter resistant
• Clear glasslike appearance
• Lightweight
• Superior moisture barrier properties

9. 2022 2023 2024 2025
1mLLong
Silicone
Free
NexCap
2.25mL
1mLShort
2.25mL DC
Auto Injector
9
1mL
Premium
Pre-Filled
Syringe Division
Product Launch
Schedule

10. 10

11. Manufacturing Capabilities
Facility Hungary SouthCarolina
Size ~40k sq ft 100k sq ft
Capacity (2023) ~50 million ~10-20 million
Potential Annual Capacity (2024) 200-300 million 50-100 million
Typesof products Disposable Syringes Pre-Filled Syringes
Cleanroom  
CustomInjection Molding  
Cleanroom Automation  
Pharma Water Systems(WFI) 
Onsite Sterilization 
Warehouse  
11

12. 2022 - 2023
50-100 MM vial drawn pieces of 1ml, 3ml, 5ml 10ml begin Q4-22
Complete development work for first PFS concepts
Commercialize first generation of Innovative PFS systems
2024 - 2025
250 MM vial drawn pieces with planned expansion at our EU plant
Increase capacity for US PFS operations
Development of new packaging concepts for Pharma Service Program
12
Manufacturing Plan

13. 25 years of healthcare experience
including drug delivery and syringe
development. Former Sr. Director
with Gerresheimer and leadership
positions with Baxter, Cardinal
Health, Coviden, Boston Scientific
and Fresenius Healthcare. Previous
experience in Manufacturing,
Product Innovation & Global Sales.
Leadership Team
Former Merck President,
Europe, Canada, Middle East
& Africa and SVP for Merck
Vaccines. P&L responsibility for
$10 B in business.
30 years experience in medical
device sales and distribution
including IV sets, dopler
monitoring, total hip
replacements, surgical stapling
and cold sterilant technology.
11
3

14. • Headquarters:
• Common Shares Outstanding (STSS: $1.00)
• Float:
• Warrants (STSSW: $0.38):
• Fully Diluted Shares Outstanding:
• Insider ownership:
• Institutional Ownership:
• Revenue:
• Cash:
• Debt
• Manufacturing Capabilities:
• Employees:
Melville, NY
9.2M shares
~5M shares
8.5MM
17.7M
~40%
NA
Pre-rev with sales expected 1H & beyond
~$6.5M (Burn is ~$500,000)
0
Hungary (STSS) & S.C. (Nephron)
60
KeyStatistics
14

15. Conclusion
 Strong commercially available product line of patented smart safety syringe products that are FDA, WHO and
CE Mark approved and cleared for use by Pfizer and Moderna.
• Nephron collaboration accelerates near-term path for (PFS) commercialization and expanded manufacturing
 Transformative manufacturing agreement to produce with a state-of-the-art manufacturing facility.
 Pharma Services Program to develop a pipeline for future growth w/specialized packaging opportunities to
support fill / finish projects for industry customers
 Specialized distribution and sales agreement for Sharps products with access to 3000+ customers
 Opportunity to expand manufacturing capabilities for growth initiatives w/100 million additional PFS
products
• Growing specialty syringe market that includes all applications targeting healthcare and pharma customers
• Strong management team with extensive experience in drug delivery manufacturing and product development
15

16. Thank you!
To learn more, please visit
SharpsTechnology.com

17. Support Information

18. Co-Founder of the company and
inventor of the Sharps ProvensaTM
line of safety syringes. 20+ years of
experience in medical research and
development (R&D) for injection
molds for safety syringe products,
and holds eight patents for safety
syringe products.
Leadership Team
Served in various finance roles from
2006 to 2019 in biotech,
manufacturing and distribution,
including, CFO of United Metro
Energy; Senior VP of Finance of
Enzo Biochem (NYSE:ENZ). Prior
to 2006, he was an Executive
Director from 2002 to 2006 and a
Senior Manager from 1997 to 2002
at Grant Thornton LLP.
Dr. Hertz divides his time with a
continuing role as Chief of Vascular
Surgery at Saint Barnabas Medical
Center and Site Director of the
Vascular Fellowship teaching
program. He has extensive
consulting experience for medical
devices and previously served
as President of the Vascular Society
of New Jersey.
18

19. Board of Directors
BRENDA SIMPSON, DNP, RN,
CENP
DR. JASON MONROE 19